These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23326927)

  • 21. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Monami M; Dicembrini I; Mannucci E
    Acta Diabetol; 2017 Jan; 54(1):19-36. PubMed ID: 27488726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
    Asrih M; Gariani K
    Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
    Miller K; Miller EM
    J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dapagliflozin: Beyond glycemic control in the treatment of type 2 diabetes mellitus].
    Sanz-Serra P; Pedro-Botet J; Flores-Le Roux JA; Benaiges D; Chillarón JJ
    Clin Investig Arterioscler; 2015; 27(4):205-11. PubMed ID: 25648671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
    Dutta D; Kalra S
    J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter.
    Toderika Y; Ferguson N
    Cardiol Rev; 2014; 22(2):97-104. PubMed ID: 24500116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT-2 inhibitors in development for type 2 diabetes treatment.
    Bhartia M; Tahrani AA; Barnett AH
    Rev Diabet Stud; 2011; 8(3):348-54. PubMed ID: 22262072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
    Zhang Q; Dou J; Lu J
    Diabetes Res Clin Pract; 2014 Sep; 105(3):313-21. PubMed ID: 25015317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
    Matthaei S
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
    [No Abstract]   [Full Text] [Related]  

  • 39. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
    Basile J
    Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
    Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.